Ecem Önder Tokuç, V Levent Karabaş, Mehmet Orkun Sevik, Fatih Bilgehan Kaplan, Işıl Kutlutürk Karagöz, Hatice Selen Kanar, Uğur Yayla, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Nimet Yeşim Erçalık, Esra Kumral Türkseven, Özlem Aydın Öncü, Erkan Çelik, Ece Başaran Emengen, Abdullah Özkaya, Banu Açıkalın Öncel, Nursal Melda Yenerel, Özlem Şahin
{"title":"雷尼珠单抗和阿夫利拜因对缩小糖尿病囊样黄斑水肿最大囊肿直径的疗效：MARMASIA研究小组。","authors":"Ecem Önder Tokuç, V Levent Karabaş, Mehmet Orkun Sevik, Fatih Bilgehan Kaplan, Işıl Kutlutürk Karagöz, Hatice Selen Kanar, Uğur Yayla, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Nimet Yeşim Erçalık, Esra Kumral Türkseven, Özlem Aydın Öncü, Erkan Çelik, Ece Başaran Emengen, Abdullah Özkaya, Banu Açıkalın Öncel, Nursal Melda Yenerel, Özlem Şahin","doi":"10.1177/11206721241280737","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the effect of intravitreal aflibercept (IVA) and ranibizumab (IVR) on the maximal diameter of the largest intraretinal cyst (mdIRC), indicating chronicity in patients with diabetic cystoid macular edema (CME).</p><p><strong>Methods: </strong>This retrospective, comparative study included a subgroup of patients from the MARMASIA Study with treatment-naïve diabetic CME who had IVA (IVA group) or IVR (IVR group) on a pro re nata regimen after a loading dose of 3-monthly injections and followed-up for 24 months. Best-corrected visual acuity (logMAR), central macular thickness (CMT, µm), and mdIRC (µm) and their changes during the study period in the IVA and IVR groups were compared.</p><p><strong>Results: </strong>A total of 175 eyes (65 [37.1%] in IVA and 110 [62.9%] in IVR group) of 113 patients were included in the study analysis. Both groups had statistically significant improvements in BCVA and CMT during the follow-up (p < 0.05 for all), which were comparable between the groups at each time point. However, the mean reduction in mdIRCs was consistently and significantly higher in the IVA group compared to the IVR group at each follow-up examination (F[1, 3.52] = 6.93, p = 0.009).</p><p><strong>Conclusion: </strong>IVA seems to have a greater impact in reducing cyst sizes than IVR in diabetic CME.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group.\",\"authors\":\"Ecem Önder Tokuç, V Levent Karabaş, Mehmet Orkun Sevik, Fatih Bilgehan Kaplan, Işıl Kutlutürk Karagöz, Hatice Selen Kanar, Uğur Yayla, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Nimet Yeşim Erçalık, Esra Kumral Türkseven, Özlem Aydın Öncü, Erkan Çelik, Ece Başaran Emengen, Abdullah Özkaya, Banu Açıkalın Öncel, Nursal Melda Yenerel, Özlem Şahin\",\"doi\":\"10.1177/11206721241280737\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to compare the effect of intravitreal aflibercept (IVA) and ranibizumab (IVR) on the maximal diameter of the largest intraretinal cyst (mdIRC), indicating chronicity in patients with diabetic cystoid macular edema (CME).</p><p><strong>Methods: </strong>This retrospective, comparative study included a subgroup of patients from the MARMASIA Study with treatment-naïve diabetic CME who had IVA (IVA group) or IVR (IVR group) on a pro re nata regimen after a loading dose of 3-monthly injections and followed-up for 24 months. Best-corrected visual acuity (logMAR), central macular thickness (CMT, µm), and mdIRC (µm) and their changes during the study period in the IVA and IVR groups were compared.</p><p><strong>Results: </strong>A total of 175 eyes (65 [37.1%] in IVA and 110 [62.9%] in IVR group) of 113 patients were included in the study analysis. Both groups had statistically significant improvements in BCVA and CMT during the follow-up (p < 0.05 for all), which were comparable between the groups at each time point. However, the mean reduction in mdIRCs was consistently and significantly higher in the IVA group compared to the IVR group at each follow-up examination (F[1, 3.52] = 6.93, p = 0.009).</p><p><strong>Conclusion: </strong>IVA seems to have a greater impact in reducing cyst sizes than IVR in diabetic CME.</p>\",\"PeriodicalId\":12000,\"journal\":{\"name\":\"European Journal of Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11206721241280737\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241280737","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group.
Purpose: This study aimed to compare the effect of intravitreal aflibercept (IVA) and ranibizumab (IVR) on the maximal diameter of the largest intraretinal cyst (mdIRC), indicating chronicity in patients with diabetic cystoid macular edema (CME).
Methods: This retrospective, comparative study included a subgroup of patients from the MARMASIA Study with treatment-naïve diabetic CME who had IVA (IVA group) or IVR (IVR group) on a pro re nata regimen after a loading dose of 3-monthly injections and followed-up for 24 months. Best-corrected visual acuity (logMAR), central macular thickness (CMT, µm), and mdIRC (µm) and their changes during the study period in the IVA and IVR groups were compared.
Results: A total of 175 eyes (65 [37.1%] in IVA and 110 [62.9%] in IVR group) of 113 patients were included in the study analysis. Both groups had statistically significant improvements in BCVA and CMT during the follow-up (p < 0.05 for all), which were comparable between the groups at each time point. However, the mean reduction in mdIRCs was consistently and significantly higher in the IVA group compared to the IVR group at each follow-up examination (F[1, 3.52] = 6.93, p = 0.009).
Conclusion: IVA seems to have a greater impact in reducing cyst sizes than IVR in diabetic CME.
期刊介绍：
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
